MIR223

Summary

MIR223 (microRNA 223, HGNC:31603) is a microRNA gene on chromosome Xq12.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407008 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31603
Approved symbol	MIR223
Name	microRNA 223
Location	Xq12
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-223
Ensembl gene	ENSG00000284567
Ensembl biotype	miRNA
OMIM	300694
Entrez	407008
RNAcentral	URS000037EC34 — miRNA, 110 nt, 5 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385204

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385204 — 1 exons

Exon	Start	End
ENSE00001500210	66018870	66018979

Expression profiles

Bgee: expression breadth broad, 31 present calls, max score 89.43.

Top tissues by expression

31 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	89.43	gold quality
heart left ventricle	UBERON:0002084	79.69	gold quality
sural nerve	UBERON:0015488	78.73	gold quality
adult mammalian kidney	UBERON:0000082	72.95	gold quality
gastrocnemius	UBERON:0001388	69.57	gold quality
ascending aorta	UBERON:0001496	68.79	gold quality
adrenal gland	UBERON:0002369	66.96	gold quality
tibial artery	UBERON:0007610	66.96	gold quality
right frontal lobe	UBERON:0002810	65.06	gold quality
right atrium auricular region	UBERON:0006631	63.59	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	62.44	gold quality
tibial nerve	UBERON:0001323	59.57	gold quality
minor salivary gland	UBERON:0001830	59.54	gold quality
right hemisphere of cerebellum	UBERON:0014890	59.26	gold quality
cerebral cortex	UBERON:0000956	59.02	gold quality
caudate nucleus	UBERON:0001873	58.51	gold quality
skin of leg	UBERON:0001511	57.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	54.66	gold quality
anterior cingulate cortex	UBERON:0009835	54.53	gold quality
pituitary gland	UBERON:0000007	53.92	gold quality
left lobe of thyroid gland	UBERON:0001120	53.34	gold quality
esophagus mucosa	UBERON:0002469	51.05	gold quality
thyroid gland	UBERON:0002046	50.21	gold quality
subcutaneous adipose tissue	UBERON:0002190	50.08	gold quality
thoracic mammary gland	UBERON:0005200	49.80	gold quality
putamen	UBERON:0001874	48.95	gold quality
right lobe of thyroid gland	UBERON:0001119	44.02	gold quality
liver	UBERON:0002107	43.63	silver quality
left coronary artery	UBERON:0001626	39.73	silver quality
testis	UBERON:0000473	39.72	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, E2F1, MLXIP, NFIA, SPI1, TP53

Literature-anchored findings (GeneRIF, showing 40)

• miR-223 is a direct transcriptional target of AML1/ETO (PMID:17996649)
• Expression levels of miR-223 in recurrent ovarian cancer. (PMID:18442408)
• potential importance of miR-223 down-regulatons in the development of hepatocellular carcinoma (PMID:18555017)
• miR-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells via down-modulation of LMO2. (PMID:19017354)
• GC-enriched hsa-miR-125b down-regulates the expression of IRF4 and PRDM1/BLIMP1, and memory B cell-enriched hsa-miR-223 down-regulates the expression of LMO2. (PMID:19047678)
• miR-29c and miR-223 expression levels decreased significantly with DISEASE progression in chronic lymphocytic leukemia (PMID:19144983)
• the myeloid-specific miR-223 and the apoptosis and cell cycle arrest-inducing miR15 ~ 16 clusters were regulated by glucocorticoids in acute lymphoblastic leukemia (PMID:19148136)
• decline of miR-223 is an important event for erythroid differentiation that leads to the expansion of erythroblast cells at least partially mediated by unblocking LMO2 protein expression (PMID:19278969)
• miRNAs (miR-142-5p, -155, and -223) are overexpressed in biopsies in acute rejection of kidney transplants (PMID:19289845)
• miR-223 as overexpressed in CD4(+) naive T-lymphocytes from rheumatoid arthritis patients (PMID:19931339)
• Our results suggest that miR-223 suppression in AML is caused by impaired miR-223 upstream factors (PMID:20018373)
• miR-223 is down-regulated in different subtypes of acute myeloid leukemia (AML). E2F1 binds to the miR-223 promoter in AML blast cells and inhibits miR-223 transcription. (PMID:20029046)
• Demonstrate a role for miR-223 in Glut4 regulation and glucose metabolism in the heart. (PMID:20080987)
• Serum miR-146a and miR-223 might serve as new biomarkers for sepsis with high specificity and sensitivity. (PMID:20188071)
• identified a subset of adult T-cell acute lymphoblastic leukemia, accounting for 10% of the cases analyzed, which displays myeloid features and had significantly higher levels of miR-223 (PMID:20418243)
• Aberrant E2A expression is a diagnostic feature of a subtype of gastric MALT lymphoma with weaker plasmacytoid infiltrates and stronger miR-223 expression. (PMID:20802470)
• miR-223 expression is responsive to acute alterations in cyclin E regulation by the Fbw7 pathway. (PMID:20826802)
• Both miR-142 and miR-223 attenuated the proliferation of hematopoietic cells and that miR-223 up-regulated miR-142 expression through the LMO2-L/-S isoforms and CEBP-beta. (mir-223) (PMID:20856265)
• miR-21, miR-122 and miR-223 are elevated in patients with hepatocellular carcinoma (HCC) or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC. (PMID:21229610)
• These results reveal that ARTN, a known tumor metastasis-related gene, is a direct target of miR-223. (PMID:21453483)
• miR-223 is overexpressed only in metastatic gastric cancer cells and stimulated nonmetastatic gastric cancer cells migration and invasion. (PMID:21628394)
• Our study provides evidence for the delivery of invasion-potentiating miR-223 by IL-4-activated macrophages to breast cancer cells via exosomes (PMID:21939504)
• This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the peripheral blood mononuclear cells of osteoarthritis patients might be related to the pathogenesis of osteoarthritis. (PMID:22006119)
• We demonstrated that niR-223 is over-expressed in T-lymphocytes of early rheumatoid arthritis patients. (PMID:22032299)
• MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. (PMID:22145958)
• The miR-223 may have significant role in the acute rejection of kidney transplantation. (PMID:22238823)
• miR-223 targets FBXW7/hCdc4 expression at the post-transcriptional level and appears to regulate cellular apoptosis, proliferation, and invasion in gastric cancer. (PMID:22270966)
• miR-223 contributes to IGF1R regulation, but may act in concert with other genes and/or microRNAs to alter T-cell acute lymphoblastic leukemia biology. (PMID:22424712)
• confirmed that STMN1 is a putative downstream target of miR-223 in gastric cancer (PMID:22470493)
• Data suggest that proliferation of neoplastic cell lines is greatly inhibited when miR-223 is over-expressed; FOXO1 is down-regulated in cytoplasm, while nuclear FOXO1 is high compared to cytoplasm. (PMID:22569260)
• MiR-223 is intensely expressed in rheumatoid arthritis synovium, and overexpression of miR-223 suppresses osteoclastogenesis in vitro. (PMID:22903258)
• The expression of miR-223 has no relationship with the immunophenotypes of diffuse large B-cell lymphoma. (PMID:22932402)
• Overexpression of miR-223 prevents accumulation of NLRP3 protein and inhibits interleukin (IL)-1beta production from the inflammasome. (PMID:22984081)
• Myeloid-specific miR-223 is identified as another critical regulator of NLRP3 inflammasome activity. (PMID:22984082)
• Expression levels of miR-223 were significantly higher in patients with mild sepsis (p < 0.001) and patients with severe sepsis and septic shock (p < 0.001) than in normal controls (PMID:23026916)
• 4 miRNAs including miR-17, miR-20a, miR-29c, and miR-223 were found to be expressed differentially in the serum of NPC compared with that of non-cancerous control (PMID:23056289)
• Inorganic phosphate-induced migration of vascular smooth muscle cells and their calcification are mediated via expression regulation of miR-223. (PMID:23094093)
• Data indicate that miR-223 was transported to target cells and was functionally active. (PMID:23144169)
• Changes in miR-223/PTBP2 pathway could contribute to abnormal splicing in chronic myeloid leukemia. (PMID:23174904)
• Hsp90B1 is a direct target of miR-223 and miR- 223 may have a tumor suppressor function in osteosarcoma through the PI3K/Akt/mTOR pathway. (PMID:23208072)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir223	ENSDARG00000080589
mus_musculus	Mir223	ENSMUSG00000076066
rattus_norvegicus	Mir223	ENSRNOG00000035505

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.